(HealthDay News) — The U.S. Food and Drug Administration has approved Penmenvy (Meningococcal Groups A, B, C, W, and Y Vaccine) for active immunization against invasive meningococcal disease (IMD), ...

Pfizer’s two-year run with the only 5-in-1 meningococcal vaccine on the U.S. market has come to an end. Now, GSK is ready to ...

The U.S. Food and Drug Administration approved British drugmaker GSK's combination vaccine to protect against meningococcal ...

Thousands of U.S. health agency employees were terminated and told it was for poor performance, though they'd received strong ...

Penmenvy combines the antigenic components of Bexsero (meningococcal Group B vaccine) and Menveo (meningococcal Groups A, C, Y, and W-135 oligosaccharide diphtheria CRM197 conjugate vaccine).

Penmenvy, which protects against five common types of disease-causing bacteria, is cleared for use in people aged 10 through ...

GSK's Penmenvy wins FDA approval to protect against five meningococcal serogroups. The CDC panel will vote on usage ...

The studies confirmed that the vaccine has a safety profile consistent with the licensed meningococcal vaccines of GSK. The ...

A Centers for Disease Control and Prevention vaccine advisory committee meeting scheduled for next week — the first since ...

Secretary Robert F. Kennedy Jr. has made waves during his first week in office, pulling promotional vaccine ads and ...

Tony Wood, Chief Scientific Officer, GSK, said: "We are excited about the opportunities ahead to help improve meningococcal vaccination coverage in the United States, especially for IMD caused by ...

The FDA approved GSK’s pentavalent meningococcal vaccine to protect children and young adults aged 10 to 25 years against ...